C. Creech, E. Anderson, V. Berthaud, Í. Yildirim, AM Atz, I. M. Baez, D. Finkelstein, P. Pickrell, J. Kirstein, C. Yut, R. Blair, RA Clifford, M. Dunn, JD Campbell, D. Montefiori, JE Tomassini, X. Zhao, W. Deng, H. Zhou, D. Schrempp, K. Hautzinger, B. Girard, K. Slobod, R. McPhee, R. Pajon, R. Das, Jm Miller, S. S. Ghamloush
The PLSP summarizes results from the phase 2/3 KidCOVE trial examining mRNA-1273 (Moderna's COVID-19 vaccine) in children 6 through 11 years of age. This study reviewed results from two parts of the KidCOVE clinical trial: Part 1 of the study was performed to select a dose of mRNA-1273 (50 μg or 100 μg) in children. A 50-μg dose was selected for further evaluation based on minimally unwanted side effects and sufficient antibodies (immune responses) against SARS-CoV-2. Part 2 of the study further evaluated the 50-μg dose of mRNA-1273 and compared it with placebo in children. Two 50-μg doses of mRNA-1273 were well tolerated with no new safety concerns. Two 50-μg doses also produced antibodies (immune responses) similar to those in young adults who received mRNA-1273 (100 μg) in a separate phase 3 study (the COVE trial). Study findings suggest that two 50-μg doses of mRNA-1273 were well-tolerated, and can prevent COVID-19 in children 6 through 11 years of age. Clinical Trial Registration: NCT04796896 ( ClinicalTrials.gov )
{"title":"Plain Language Summary of a Clinical Trial Evaluating mRNA-1273, Moderna's mRNA-Based COVID-19 Vaccine, in Children 6 Through 11 Years of Age","authors":"C. Creech, E. Anderson, V. Berthaud, Í. Yildirim, AM Atz, I. M. Baez, D. Finkelstein, P. Pickrell, J. Kirstein, C. Yut, R. Blair, RA Clifford, M. Dunn, JD Campbell, D. Montefiori, JE Tomassini, X. Zhao, W. Deng, H. Zhou, D. Schrempp, K. Hautzinger, B. Girard, K. Slobod, R. McPhee, R. Pajon, R. Das, Jm Miller, S. S. Ghamloush","doi":"10.2217/fvl-2023-0020","DOIUrl":"https://doi.org/10.2217/fvl-2023-0020","url":null,"abstract":"The PLSP summarizes results from the phase 2/3 KidCOVE trial examining mRNA-1273 (Moderna's COVID-19 vaccine) in children 6 through 11 years of age. This study reviewed results from two parts of the KidCOVE clinical trial: Part 1 of the study was performed to select a dose of mRNA-1273 (50 μg or 100 μg) in children. A 50-μg dose was selected for further evaluation based on minimally unwanted side effects and sufficient antibodies (immune responses) against SARS-CoV-2. Part 2 of the study further evaluated the 50-μg dose of mRNA-1273 and compared it with placebo in children. Two 50-μg doses of mRNA-1273 were well tolerated with no new safety concerns. Two 50-μg doses also produced antibodies (immune responses) similar to those in young adults who received mRNA-1273 (100 μg) in a separate phase 3 study (the COVE trial). Study findings suggest that two 50-μg doses of mRNA-1273 were well-tolerated, and can prevent COVID-19 in children 6 through 11 years of age. Clinical Trial Registration: NCT04796896 ( ClinicalTrials.gov )","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48170881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Asma Bouazizi, Mouna Ben Hadj Fredj, A. Jerbi, Haifa Bennour, I. Fodha, A. Trabelsi
Aim: To evaluate human adenovirus (HAdV) types associated with respiratory infections, nasopharyngeal aspirations (NPA) were collected from children under 2 years old that were hospitalized for acute respiratory tract infections (ARTI) during 2018–2019. Methods: PCR was used for viral screening and select samples were then sequenced by Sanger sequencing. Results: Among 194 samples, 30 were HAdV-positive and 14 were chosen for further sequencing. HAdV-F41, C2 and C5 circulated simultaneously with an unexpected predominance of HAdV-F41. HAdV infection occurred year-round, with a peak in winter and early spring. The age group most affected was those younger than 6 months. Conclusion: Continued surveillance of HAdV infections is necessary and the contribution of HAdV-F41 in ARTI should be studied.
{"title":"Unexpected predominance of human adenovirus F41 in children suffering from acute respiratory infection in Tunisia","authors":"Asma Bouazizi, Mouna Ben Hadj Fredj, A. Jerbi, Haifa Bennour, I. Fodha, A. Trabelsi","doi":"10.2217/fvl-2022-0215","DOIUrl":"https://doi.org/10.2217/fvl-2022-0215","url":null,"abstract":"Aim: To evaluate human adenovirus (HAdV) types associated with respiratory infections, nasopharyngeal aspirations (NPA) were collected from children under 2 years old that were hospitalized for acute respiratory tract infections (ARTI) during 2018–2019. Methods: PCR was used for viral screening and select samples were then sequenced by Sanger sequencing. Results: Among 194 samples, 30 were HAdV-positive and 14 were chosen for further sequencing. HAdV-F41, C2 and C5 circulated simultaneously with an unexpected predominance of HAdV-F41. HAdV infection occurred year-round, with a peak in winter and early spring. The age group most affected was those younger than 6 months. Conclusion: Continued surveillance of HAdV infections is necessary and the contribution of HAdV-F41 in ARTI should be studied.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44313358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Igarashi, K. Togo, Yasuhiro Kobayashi, Kazumasa Kamei, N. Yonemoto, N. Ishiwada
Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDV-infant (n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged <1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and OAs.
{"title":"Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults","authors":"A. Igarashi, K. Togo, Yasuhiro Kobayashi, Kazumasa Kamei, N. Yonemoto, N. Ishiwada","doi":"10.2217/fvl-2023-0069","DOIUrl":"https://doi.org/10.2217/fvl-2023-0069","url":null,"abstract":"Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDV-infant (n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged <1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and OAs.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42605802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: This study aimed to present the characteristics and poor prognostic factors of Crimean–Congo hemorrhagic fever (CCHF) patients. Materials & methods: Adult patients (>18 years) with CCHF were included in this retrospective study. Demographics, risk scores and laboratory findings of survivors and nonsurvivors were compared. Results: Fifteen (9.2%) of 163 CCHF patients were nonsurvivors and had a higher Severity Score Index (p < 0.001), Severity Grade Score (p < 0.001) and De Ritis ratio (aspartate transaminase/alanine transaminase) (p < 0.001). De Ritis ratio was >3 in 10.1% of survivors and 53.3% of nonsurvivors (p < 0.001). In multivariate analysis, De Ritis ratio >3 (OR: 5.428, p = 0.045) and SGS (OR: 1.776, p = 0.005) were found as predictive factors. Conclusion: De Ritis ratio may predict prognosis in combination with severity risk scores in CCHF.
目的:探讨克里米亚-刚果出血热(CCHF)患者的特点及影响预后的因素。材料与方法:本回顾性研究纳入成年CCHF患者(bb0 ~ 18岁)。对幸存者和非幸存者的人口统计、风险评分和实验室结果进行比较。结果:163例CCHF患者中有15例(9.2%)为非幸存者，严重程度评分指数(severe Score Index)较高(10.1%的幸存者为3,53.3%的非幸存者为3 (p = 5.428, p = 0.045)和SGS (OR: 1.776, p = 0.005)为预测因素。结论:De - Ritis比值可与CCHF严重危险评分联合预测预后。
{"title":"The association of De Ritis ratio with the severity of Crimean–Congo hemorrhagic fever","authors":"Esma Eryilmaz-Eren, Ayse Turunc-Ozdemir, Azade Kanat, Zeynep Ture, Ayşin Kılınç-Toker, I. Çelik","doi":"10.2217/fvl-2023-0008","DOIUrl":"https://doi.org/10.2217/fvl-2023-0008","url":null,"abstract":"Aim: This study aimed to present the characteristics and poor prognostic factors of Crimean–Congo hemorrhagic fever (CCHF) patients. Materials & methods: Adult patients (>18 years) with CCHF were included in this retrospective study. Demographics, risk scores and laboratory findings of survivors and nonsurvivors were compared. Results: Fifteen (9.2%) of 163 CCHF patients were nonsurvivors and had a higher Severity Score Index (p < 0.001), Severity Grade Score (p < 0.001) and De Ritis ratio (aspartate transaminase/alanine transaminase) (p < 0.001). De Ritis ratio was >3 in 10.1% of survivors and 53.3% of nonsurvivors (p < 0.001). In multivariate analysis, De Ritis ratio >3 (OR: 5.428, p = 0.045) and SGS (OR: 1.776, p = 0.005) were found as predictive factors. Conclusion: De Ritis ratio may predict prognosis in combination with severity risk scores in CCHF.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48785601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Hakim, S. Bibi, Q. Ali, Bisma Sarfraz, Y. Arshad, Z. Rehman, M. Salman, A. Ikram, M. Umair
Aim: The current study aimed to identify prevalent dengue serotypes during a major outbreak in 2021 in Pakistan. Materials & methods: From September-November 2021, 373 serum samples from different provinces were tested by RT-PCR for serotype identification, followed by partial sequence analysis of selected dengue-positive samples. Results: Out of 373 samples, 273 (73%) were positive for dengue virus infection with male predominance (61.9%). Complete predominance of DENV-2 serotype (99%) and a single case of DENV-1 was observed. Sequencing data revealed the presence of a cosmopolitan genotype within the DENV-2 Pakistani isolates. Conclusion: This study highlights the persistent predominance of DENV-2 during the 2021 outbreak, suggesting a need to improve surveillance strategies and vector breeding control programs in Pakistan.
{"title":"Molecular epidemiology of dengue virus circulating during 2021 outbreak in Pakistan","authors":"R. Hakim, S. Bibi, Q. Ali, Bisma Sarfraz, Y. Arshad, Z. Rehman, M. Salman, A. Ikram, M. Umair","doi":"10.2217/fvl-2022-0196","DOIUrl":"https://doi.org/10.2217/fvl-2022-0196","url":null,"abstract":"Aim: The current study aimed to identify prevalent dengue serotypes during a major outbreak in 2021 in Pakistan. Materials & methods: From September-November 2021, 373 serum samples from different provinces were tested by RT-PCR for serotype identification, followed by partial sequence analysis of selected dengue-positive samples. Results: Out of 373 samples, 273 (73%) were positive for dengue virus infection with male predominance (61.9%). Complete predominance of DENV-2 serotype (99%) and a single case of DENV-1 was observed. Sequencing data revealed the presence of a cosmopolitan genotype within the DENV-2 Pakistani isolates. Conclusion: This study highlights the persistent predominance of DENV-2 during the 2021 outbreak, suggesting a need to improve surveillance strategies and vector breeding control programs in Pakistan.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42850592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: Epstein–Barr virus-related Burkitt's lymphoma (BL) is characterized by EBNA1 expression. Previous studies have hypothesized a correlation between Burkitt's lymphoma and endemicity of Euphorbia spp. whereas others have suggested it possesses antiviral activity. We aimed to investigate the effect of Euphorbia spp. on BL. Methods: AutoDock Vina, GROMACS 2020.4 and VEGA-QSAR were used for in silico assessments. Results: Daphnoretin had a higher binding affinity than the EBNA1 inhibitor VK0044, maintained a steady ligand RMSD value and displayed the largest negative binding energy at the EBNA1 active site. Conclusion: Daphnoretin, a phytochemical of Euphorbia spp., had superior inhibitory activity of EBNA1 over other tested chemicals, suggesting it is an effective therapeutic drug candidate.
{"title":"Friend or foe: association of Euphorbia spp. with Epstein–Barr virus and Burkitt's lymphoma, an in silico approach","authors":"E. Erdag, Ismet Ersalici, Cenk Serhan Ozverel","doi":"10.2217/fvl-2023-0011","DOIUrl":"https://doi.org/10.2217/fvl-2023-0011","url":null,"abstract":"Aim: Epstein–Barr virus-related Burkitt's lymphoma (BL) is characterized by EBNA1 expression. Previous studies have hypothesized a correlation between Burkitt's lymphoma and endemicity of Euphorbia spp. whereas others have suggested it possesses antiviral activity. We aimed to investigate the effect of Euphorbia spp. on BL. Methods: AutoDock Vina, GROMACS 2020.4 and VEGA-QSAR were used for in silico assessments. Results: Daphnoretin had a higher binding affinity than the EBNA1 inhibitor VK0044, maintained a steady ligand RMSD value and displayed the largest negative binding energy at the EBNA1 active site. Conclusion: Daphnoretin, a phytochemical of Euphorbia spp., had superior inhibitory activity of EBNA1 over other tested chemicals, suggesting it is an effective therapeutic drug candidate.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46463402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Noorossadat Seyyedi, Fariba Esfandiyari, Gholamreza Rafiei Dehbidi, A. Farhadi, F. Zare, S. Namdari, Golrokh Bahmani, Banafsheh Rastegari, Farzaneh Zarghampoor, A. Behzad-Behbahani
Aim: This study investigated the correlation between anti-thyroid peroxidase (anti-TPO) antibody levels and human herpesvirus 6 (HHV-6) viral load as triggers for Hashimoto's thyroiditis (HT). Materials & methods: The study included 60 HT patients, 60 patients with non-autoimmune thyroid disease, and 60 subjects with normal thyroid function. HHV-6 viral loads in serum samples were detected using real-time PCR. Results: A significant correlation was found between the increase in viral load and increased levels of anti-TPO antibodies in serum samples from HT patients (p = 0.001). Conclusion: The aim of this study was to explore the potential involvement of HHV-6A in the onset of HT, with the goal of identifying improved treatment options for affected individuals.
{"title":"Correlation analysis of HHV-6A viral load and anti-TPO antibody levels in patients with Hashimoto's thyroiditis","authors":"Noorossadat Seyyedi, Fariba Esfandiyari, Gholamreza Rafiei Dehbidi, A. Farhadi, F. Zare, S. Namdari, Golrokh Bahmani, Banafsheh Rastegari, Farzaneh Zarghampoor, A. Behzad-Behbahani","doi":"10.2217/fvl-2022-0194","DOIUrl":"https://doi.org/10.2217/fvl-2022-0194","url":null,"abstract":"Aim: This study investigated the correlation between anti-thyroid peroxidase (anti-TPO) antibody levels and human herpesvirus 6 (HHV-6) viral load as triggers for Hashimoto's thyroiditis (HT). Materials & methods: The study included 60 HT patients, 60 patients with non-autoimmune thyroid disease, and 60 subjects with normal thyroid function. HHV-6 viral loads in serum samples were detected using real-time PCR. Results: A significant correlation was found between the increase in viral load and increased levels of anti-TPO antibodies in serum samples from HT patients (p = 0.001). Conclusion: The aim of this study was to explore the potential involvement of HHV-6A in the onset of HT, with the goal of identifying improved treatment options for affected individuals.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48157034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti
Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )
{"title":"Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study","authors":"A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti","doi":"10.2217/fvl-2023-0065","DOIUrl":"https://doi.org/10.2217/fvl-2023-0065","url":null,"abstract":"Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41745798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ya-Ping Hou, Cheng Fan, Qing-Qing Jiang, Lei Wu, Ying Luo
Aim: Human papillomavirus (HPV) is the most common cause of high-grade lesions and carcinogenesis such as cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). The prevalence and genotype distribution of HPV infection varies greatly in different geographical areas. Patients & methods: This study enrolled 92,932 patients from January 2017 to December 2021 and analyzed the prevalence and distribution of HPV genotypes. Results: 18038 (19.41%) specimens were HPV-positive. No significant difference in infection rates between men and women (19.05 vs 19.41%). The most prevalent HPV subtypes are HPV52, HPV58, HPV16, HPV53, HPV51 and HPV81. Single infection of HPV has dominated in HPV-positive patients. Conclusion: Our results show that the prevalence and distribution of HPV subtypes have obvious region-specific and age-specific characteristics.
{"title":"Prevalence and genotype distribution of human papillomavirus in 92,932 cases in Shanghai, China","authors":"Ya-Ping Hou, Cheng Fan, Qing-Qing Jiang, Lei Wu, Ying Luo","doi":"10.2217/fvl-2022-0180","DOIUrl":"https://doi.org/10.2217/fvl-2022-0180","url":null,"abstract":"Aim: Human papillomavirus (HPV) is the most common cause of high-grade lesions and carcinogenesis such as cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). The prevalence and genotype distribution of HPV infection varies greatly in different geographical areas. Patients & methods: This study enrolled 92,932 patients from January 2017 to December 2021 and analyzed the prevalence and distribution of HPV genotypes. Results: 18038 (19.41%) specimens were HPV-positive. No significant difference in infection rates between men and women (19.05 vs 19.41%). The most prevalent HPV subtypes are HPV52, HPV58, HPV16, HPV53, HPV51 and HPV81. Single infection of HPV has dominated in HPV-positive patients. Conclusion: Our results show that the prevalence and distribution of HPV subtypes have obvious region-specific and age-specific characteristics.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42220904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Ghorbani, Vahid Tambrchi, Rana Farzi, A. Khatami, Rahil Nahid Samiei, H. Saadati, M. Noori, Arash Letafati, Atefeh Bahavar, Noorin Hezarpishe, Mehrshid Musavioun, Bahareh Mirzaei, Mohadeseh Sadat Meftagh, Najme Khodaei Doust, Fatemeh Hejami, S. J. Kiani
Aim: The aim of this study was to investigate the pooled prevalence and potential correlation between Epstein–Barr virus (EBV) infection and brain cancers. Materials & methods: We searched for relevant studies in main databases and analyzed the heterogeneity, odds ratio and corresponding 95% CI among all studies using STATA software V.14. Results: Fourteen articles were included in the meta-analysis. The pooled prevalence of EBV among brain cancer patients was 9% (95% CI: 3–16%; I2 = 91.06%). An association was found between EBV and brain cancer (OR: 6.90 [95% CI: 1.81–26.28]; I2 = 0%]). Conclusion: The results of this study indicate a significant association between EBV infection and brain cancer, suggesting EBV infection is a potential risk factor for brain cancer development.
{"title":"Association between human Epstein–Barr virus and brain cancer: a systematic review and meta-analysis","authors":"S. Ghorbani, Vahid Tambrchi, Rana Farzi, A. Khatami, Rahil Nahid Samiei, H. Saadati, M. Noori, Arash Letafati, Atefeh Bahavar, Noorin Hezarpishe, Mehrshid Musavioun, Bahareh Mirzaei, Mohadeseh Sadat Meftagh, Najme Khodaei Doust, Fatemeh Hejami, S. J. Kiani","doi":"10.2217/fvl-2022-0219","DOIUrl":"https://doi.org/10.2217/fvl-2022-0219","url":null,"abstract":"Aim: The aim of this study was to investigate the pooled prevalence and potential correlation between Epstein–Barr virus (EBV) infection and brain cancers. Materials & methods: We searched for relevant studies in main databases and analyzed the heterogeneity, odds ratio and corresponding 95% CI among all studies using STATA software V.14. Results: Fourteen articles were included in the meta-analysis. The pooled prevalence of EBV among brain cancer patients was 9% (95% CI: 3–16%; I2 = 91.06%). An association was found between EBV and brain cancer (OR: 6.90 [95% CI: 1.81–26.28]; I2 = 0%]). Conclusion: The results of this study indicate a significant association between EBV infection and brain cancer, suggesting EBV infection is a potential risk factor for brain cancer development.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46701399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：